Patent SG-11201900482S-A (SG)
Title: Compounds and compositions as inhibitors of endosomal toll-like receptors
Inventor: ALPER PHILLIP
IPC: C07D471/04
Filed: 2017-09-06
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 15 March 2018 (15.03.2018) WIPO I PCT mu °million °nolo olomomollm oinio oimIE (10) International Publication Number WO 2018/047081 Al (51) International Patent Classification: CO7D 471/04 (2006.01) A61P 37/00 (2006.01) A61K 31/437 (2006.01) (21) International Application Number: PCT/IB2017/055375 (22) International Filing Date: 06 September 2017 (06.09.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/385,726 09 September 2016 (09.09.2016) US (71) Applicant: NOVARTIS AG [CH/CH]; Lichtstrasse 35, 4056 Basel (CH). (72) Inventors: ALPER, Phillip; Novartis Institute for Func- tional Genomics, Inc., dba Genomics Institute of the No- vartis Research Foundation, 10675 John Jay Hopkins Dri- ve, San Diego, California 92121 (US). DEANE, Jonathan; Novartis Institute for Functional Genomics, Inc., dba Ge- nomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). JIANG, Songchun; Novartis Institute for Functional Genomics, Inc., dba Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). JIANG, Tao; Novartis Institute for Functional Genomics, Inc., dba Ge- nomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). KNOEPFEL, Thomas; Novartis Pharma AG, St. Johann, Postfach, 4002 Basel (CH). MICHELLYS, Pierre-Yves; Novartis Institute for Functional Genomics, Inc., dba Genomics Institute of the Novartis Research Foun- dation, 10675 John Jay Hopkins Drive, San Diego, Cal- ifornia 92121 (US). MUTNICK, Daniel; Novartis Insti- tutes for Biomedical Research, Inc., 5300 Chiron Way, Emeryville, California 94608 (US). PEI, Wei; Novartis In- stitute for Functional Genomics, Inc., dba Genomics In- stitute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). SY- KA, Peter; Novartis Institute for Functional Genomics, Inc., dba Genomics Institute of the Novartis Research Foun- dation, 10675 John Jay Hopkins Drive, San Diego, Cali- fornia 92121 (US). ZHANG, Guobao; c/o 279 Wenjing road, Minhang District, Shanghai, Shanghai 200245 (CN). ZHANG, Yi; 171 School Street, Belmont, Massachusetts 02478 (US). (74) Agent: NOVARTIS AG; Lichtstrasse 35, 4056 Basel (CH). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.1700) Published: with international search report (Art. 21(3)) 1-1 QC (54) Title: COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS O N 71- RA N n R 17 Ot O C R 17 (57) : The invention disclosed herein relates to 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridinyl compounds and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridinyl compounds of Formula (A), pharma- R 1 ceutical compositions comprising such compounds and the use of such compounds in the treatment of (A) autoimmune diseases.